Stock, pipeline and biotech catalyst intelligence
Reported statements
| USD | 2023 |
|---|---|
| Revenue | $3.1M |
| R&D expense | $16.3M |
| Operating income | −$35.3M |
| Net income | −$40.3M |
| Cash & equivalents | $33.0M |
| Total debt | $36.2M |
| Operating cash flow | −$33.0M |
| Free cash flow | −$33.1M |
Company profile
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Feb 5, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.